Breast Cancer: Targets and Therapy (Mar 2024)
The Role of Ki-67 in HR+/HER2- Breast Cancer: A Real-World Study of 956 Patients
Abstract
Qin Ma,1 Yao-Bang Liu,2 Tong She,3 Xin-Lan Liu4 1Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, People’s Republic of China; 2Department of Surgical Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, People’s Republic of China; 3Hospital of Zhongwei, Zhongwei, People’s Republic of China; 4Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, People’s Republic of ChinaCorrespondence: Xin-Lan Liu, Tel +8613709577339, Email [email protected]: This study determined the cut-off value of Ki-67 expression and discussed the interaction between Ki-67 and histological grade, further explored the prognostic role of Ki-67 in hormone receptor-positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer;.Materials and Methods: We assessed the Ki-67 expression of 956 patients with HR+/HER2 breast cancer diagnosed in the General Hospital of Ningxia Medical University from 2015 to 2019 by immunohistochemistry (IHC), The disease-free survival (DFS) was defined as the time from postoperative to the first local recurrence, distant metastasis or death of the disease. The follow-up by means of inpatient or outpatient medical records and telephone.Results: 22.5% was used as the cut-off for low/high Ki-67 expression in HR+/HER2- breast cancer. Compared with the value of 14%, which is commonly used in clinic at present, the consistency of the two values is moderate (Kappa = 0.484, P 22.5% have a worse prognosis and are more likely to have early recurrence and metastasis.Keywords: Ki-67, breast cancer, cut-off value, histological grade, recurrence and metastasis
